Kevin Dennis Green Sells 23,147 Shares of Cerus Co. (NASDAQ:CERS) Stock

Cerus Co. (NASDAQ:CERS) CFO Kevin Dennis Green sold 23,147 shares of Cerus stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $1.45, for a total transaction of $33,563.15. Following the completion of the sale, the chief financial officer now owns 912,607 shares of the company’s stock, valued at $1,323,280.15. This trade represents a 2.47 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Kevin Dennis Green also recently made the following trade(s):

• On Friday, March 7th, Kevin Dennis Green sold 31,148 shares of Cerus stock. The stock was sold at an average price of $1.50, for a total transaction of $46,722.00.
• On Monday, March 3rd, Kevin Dennis Green sold 60,656 shares of Cerus stock. The stock was sold at an average price of $1.58, for a total transaction of $95,836.48.

Cerus Price Performance

CERS stock opened at $1.43 on Wednesday. The company has a quick ratio of 1.92, a current ratio of 2.59 and a debt-to-equity ratio of 1.19. Cerus Co. has a 12 month low of $1.38 and a 12 month high of $2.54. The firm has a market cap of $265.68 million, a P/E ratio of -13.00 and a beta of 1.56. The company’s 50-day moving average price is $1.72 and its two-hundred day moving average price is $1.75.

Cerus (NASDAQ:CERS) last released its earnings results on Thursday, February 20th. The biotechnology company reported ($0.01) EPS for the quarter, meeting the consensus estimate of ($0.01). Cerus had a negative net margin of 11.60% and a negative return on equity of 40.55%. The firm had revenue of $50.81 million for the quarter, compared to analyst estimates of $50.81 million. On average, analysts anticipate that Cerus Co. will post -0.08 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $4.00 price objective on shares of Cerus in a research note on Friday, February 21st.

Hedge Funds Weigh In On Cerus

Several hedge funds have recently bought and sold shares of the company. Los Angeles Capital Management LLC grew its holdings in shares of Cerus by 153.7% during the 3rd quarter. Los Angeles Capital Management LLC now owns 195,224 shares of the biotechnology company’s stock valued at $340,000 after purchasing an additional 118,280 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of Cerus during the 3rd quarter valued at approximately $353,000. Intech Investment Management LLC bought a new stake in shares of Cerus during the 3rd quarter valued at approximately $71,000. Charles Schwab Investment Management Inc. grew its holdings in shares of Cerus by 0.5% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,754,540 shares of the biotechnology company’s stock valued at $3,053,000 after purchasing an additional 8,707 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its holdings in shares of Cerus by 1,182.9% during the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 132,628 shares of the biotechnology company’s stock valued at $231,000 after purchasing an additional 122,290 shares during the last quarter. 78.37% of the stock is owned by institutional investors.

Cerus Company Profile

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.